Matt Herper has some thoughts on costs, the shift to value and pharmas need to change the model.
Allergan is launching a social-centric campaign for its contraceptive Lo Loesterin Fe targeting Millennials dubbed #ActuallySheCan (heres the minimalist, mobile-friendly website where you can create your Shemoji). Allergan/Actavis thinking behind the campaign is smart they recognize that consumer marketing is no longer a one-way dialogue and that its everywhere and 24/7 that the doctors office is no longer the center of the universe for pharma marketers. They also get that Millennials are cost-conscious in making healthcare decisions. Its an interesting approach, though at least one Millennial pharma reporter finds it a jumble of tired clichés about her generation.
FDA greenlighted a bolt-on smart inhaler app/sensor product from Propeller Health thats designed to work with GSKs Diskus COPD and asthma inhaler and, based on trials data, granted them permission to market claims that it can boost adherence, predict exacerbations and reduce frequency of symptoms and exacerbations for asthma and COPD.
A consortium of researchers and industry partners from the EU is developing a smart mirror which would analyze the face for signs of stress ore weight change, sniff their breath, estimate heart rate and use all the data gleaned to predict, say, an imminent heart attack.
Eyeforpharma has surveyed 316 pharma execs on the future of customer engagement. Among the findings: one-quarter still consider physicians to be their most important customer.